氢溴酸烯丙吗啡 | 1041-90-3

• 物质功能分类: 原料药 - 专科用药 - 解毒药
• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 吗啡烷
• 中文名称: 氢溴酸烯丙吗啡
• 中文别名: N-烯丙基去甲吗啡溴酸盐
• 英文名称: 17-allyl-4,5α-epoxy-morphin-7-ene-3,6α-diol; hydrobromide
• 英文别名: 17-Allyl-4,5α-epoxy-morphin-7-en-3,6α-diol; Hydrobromid；nalorphine hydrobromide；(4R,4aR,7S,7aR,12bS)-3-prop-2-enyl-2,4,4a,7,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinoline-7,9-diol;hydrobromide
• CAS: 1041-90-3
• 化学式: BrH*C₁₉H₂₁NO₃
• 分子量: 392.293
• InChiKey: GLWUOONQQABCPM-ZQGPYOJVSA-N

物化性质

• 熔点：
  126 °C

计算性质

• 辛醇/水分配系数(LogP)：
  2.33
• 重原子数：
  24
• 可旋转键数：
  2
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  52.9
• 氢给体数：
  3
• 氢受体数：
  4

文献信息

• Analgesics for nasal administration
  申请人：Birch John Phillip

  公开号：US20050142072A1

  公开（公告）日：2005-06-30

  An analgesic and a delivery agent are combined in a pharmaceutical composition such that, on introduction into the nasal cavity of a patient to be treated, the analgesic may be delivered to the bloodstream to produce within 30 minutes a therapeutic plasma concentration, C ther , of 0.2 ng/ml or greater which is maintained for a duration T maint of at least 2 hours. The analgesic may be an opioid analgesic or a non-steroidal anti-inflammatory drug.

  一种镇痛剂和传递剂被组合在一种制药组合物中，以便在引入到需要治疗的患者的鼻腔中时，镇痛剂可以被传递到血液中，在30分钟内产生治疗性血浆浓度Cther，达到0.2ng/ml或更高，并且维持至少2小时的持续时间Tmaint。镇痛剂可以是阿片类镇痛剂或非甾体抗炎药。
• Analgesics
  申请人：Birch John Phillip

  公开号：US20070231269A1

  公开（公告）日：2007-10-04

  An analgesic and a delivery agent are combined in a pharmaceutical composition such that, on introduction into the nasal cavity of a patient to be treated, the analgesic may be delivered to the bloodstream to produce within 30 minutes a therapeutic plasma concentration, C ther , of 0.2 ng/ml or greater which is maintained for a duration T maint of at least 2 hours. The analgesic may be an opioid analgesic or a non-steroidal anti-inflammatory drug.

  一种镇痛剂和输送剂被结合在一种制药组合物中，这样，在将其引入要治疗的患者的鼻腔时，镇痛剂可以被输送到血液中，在30分钟内产生治疗性血浆浓度Cther，至少为0.2 ng/ml，并且该浓度可维持至少2小时的持续时间Tmaint。该镇痛剂可以是阿片类镇痛剂或非甾体抗炎药。
• Use of NK-1 receptor antagonist serlopitant in pruritus
  申请人：Menlo Therapeutics Inc.

  公开号：US10278953B2

  公开（公告）日：2019-05-07

  The invention relates to methods for treating pruritus with NK-1 receptor antagonists such as serlopitant. The invention further relates to pharmaceutical compositions comprising NK-1 receptor antagonists such as serlopitant. In addition, the invention encompasses treatment of a pruritus-associated condition with serlopitant and an additional antipruritic agent, and the use of serlopitant as a sleep aid, optionally in combination with an additional sleep-aiding agent.

  本发明涉及用NK-1受体拮抗剂如塞洛匹坦治疗瘙痒症的方法。本发明还涉及包含 NK-1 受体拮抗剂如塞洛匹坦的药物组合物。此外，本发明还包括用塞洛匹坦和另一种止痒剂治疗与瘙痒有关的病症，以及将塞洛匹坦用作助眠剂，可选择与另一种助眠剂联合使用。
• Use of NK-1 receptor antagonists in pruritus
  申请人：Menlo Therapeutics Inc.

  公开号：US10278952B2

  公开（公告）日：2019-05-07

  The invention relates to methods for treating pruritus with NK-1 receptor antagonists such as serlopitant. The invention further relates to pharmaceutical compositions comprising NK-1 receptor antagonists such as serlopitant. In addition, the invention encompasses treatment of a pruritus-associated condition with serlopitant and an additional antipruritic agent, and the use of serlopitant as a sleep aid, optionally in combination with an additional sleep-aiding agent.

  本发明涉及用NK-1受体拮抗剂如塞洛匹坦治疗瘙痒症的方法。本发明还涉及包含 NK-1 受体拮抗剂如塞洛匹坦的药物组合物。此外，本发明还包括用塞洛匹坦和另一种止痒剂治疗与瘙痒有关的病症，以及将塞洛匹坦用作助眠剂，可选择与另一种助眠剂联合使用。
• Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate
  申请人：The Scripps Research Institute

  公开号：US10660899B2

  公开（公告）日：2020-05-26

  The present invention provides methods of inducing differentiation of oligodendrocyte progenitor cells to a mature myelinating cell fate with a neurotransmitter receptor modulating agent. The present invention also provides methods of stimulating increased myelination in a subject in need thereof by administering said neurotransmitter receptor modulating agent. Methods of treating a subject having a demyelinating disease using a neurotransmitter receptor modulating agent are also provided.

  本发明提供了用神经递质受体调节剂诱导少突胶质祖细胞向成熟髓鞘细胞命运分化的方法。本发明还提供了通过施用所述神经递质受体调节剂刺激有需要的受试者增加髓鞘化的方法。本发明还提供了使用神经递质受体调节剂治疗脱髓鞘疾病的方法。